Safe and well tolerated
Ebixa is a safe and very well tolerated treatment, and in clinical trials the overall incidence of adverse events with Ebixa did not differ from those with placebo. Furthermore the adverse events seen are usually mild to moderate in severity.
More than 1.6 million patients have been treated with memantine worldwide (ref.1).
The following Adverse Drug Reactions listed in the table below have been accumulated in clinical studies with memantine and since its introduction in the market:
- Adverse reactions are ranked according to system organ class, using the following convention: very common (=> 1/10), common (=>1/100 to <1/10), uncommon (=>1/1,000 to =< 1/100), rare (=>1/10,000 to =< 1/1.000), very rare (=<1/10,000), not known (can not be estimated from the available data)
References:
1. H. Lundbeck A/S, Data on file, Ebixa EPAR